Focused ultrasound‐mediated APOE4 knockdown in mouse brain
Open accessAbstract
INTRODUCTION: The apolipoprotein E ( APOE ) ε4 allele is widely recognized as the strongest genetic risk factor for late‐onset Alzheimer's disease. Therapeutic strategies to reduce apoE4 expression in APOE ε4 carriers hold promise to mitigate neuroinflammatory and neurodegenerative processes driving disease progression. METHODS: Focused ultrasound (FUS) was employed to transiently open the blood–brain barrier (BBB) for efficient knockdown of humanized APOE ε4 in the mouse brain via gene editing. The all‐in‐one clustered regularly interspaced short palindromic repeats (CRISPR)–based adeno‐associated virus (AAV) vectors were administered intravenously at a dose of 1.5×10 12 vg per mouse to determine the gene‐editing efficacy within the hippocampus. RESULTS: FUS‐enhanced delivery of AAV resulted in a 12.6% knockdown of APOE ε4 gene expression in the targeted hippocampus, accompanied by an over 20% decrease in apoE4 protein levels and significant reductions in astrocyte and microglia levels. DISCUSSION: Our findings demonstrate a noninvasive, targeted approach for APOE ε4 knockdown, highlighting FUS‐mediated brain‐directed interventions as a promising therapeutic strategy for Alzheimer's disease. Highlights: Focused ultrasound (FUS) enables noninvasive, transient blood–brain barrier (BBB) opening for enhanced adeno‐associated virus (AAV) delivery. FUS‐mediated gene editing achieves a 12.6% knockdown in APOE ε4 expression within the hippocampus of mouse brain. APOE ε4 knockdown significantly reduces apoE4 protein levels and astrocyte and microglia levels. No detectable gross toxicity was observed following the FUS‐mediated gene editing.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · see citing works
Reactive astrocyte nomenclature, definitions, and future directions
Escartin, C., Galea, E., Lakatos, A., O’Callaghan, J. P., Petzold, G. C., Serrano-Pozo, A., Steinhäuser, C., Volterra, A., Carmignoto, G., Agarwal, A., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00783-4 · Cited by 2,533 · see citing works
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906 · cited 2× · see citing works
“CRISPR-Cas9 induced double-strand breaks between nucleotides 17 and 18 of the sgRNA sequence, and subsequent NHEJ repair introduced sequence diversification beyond the cleavage site, potentially leading to frameshift mutations and loss-of-function alleles.”
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,766 · cited 1× · see citing works
“70 Neverthe-less, the synthesized nanomaterials are usually larger than the 25 nm AAVs, 71,72 requiring further optimization of FUS parameters to ensure effective brain-wide delivery.”
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126 · see citing works
Clinical trial of blood-brain barrier disruption by pulsed ultrasound
Carpentier, A., Canney, M., Vignot, A., Reina, V., Beccaria, K., Horodyckid, C., Karachi, C., Leclercq, D., Lafon, C., Chapelon, J.-Y., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6086 · Cited by 757 · see citing works
Wang, C., Xiong, M., Gratuze, M., Bao, X., Shi, Y., Andhey, P. S., Manis, M., Schroeder, C., Yin, Z., Madore, C., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.03.024 · Cited by 334 · see citing works
Beyond Activation: Characterizing Microglial Functional Phenotypes
Lier, J., Streit, W. J., & Bechmann, I. (2021) · Cells · doi:10.3390/cells10092236 · Cited by 274 · see citing works
Multifaceted roles of APOE in Alzheimer disease
Jackson, R. J., Hyman, B. T., & Serrano-Pozo, A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00988-2 · Cited by 193 · see citing works
Selection of an Efficient AAV Vector for Robust CNS Transgene Expression
Hanlon, K. S., Meltzer, J. C., Buzhdygan, T., Cheng, M. J., Sena-Esteves, M., Bennett, R. E., Sullivan, T. P., Razmpour, R., Gong, Y., Ng, C., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.007 · Cited by 148 · see citing works
Mahan, T. E., Wang, C., Bao, X., Choudhury, A., Ulrich, J. D., & Holtzman, D. M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00516-0 · Cited by 134 · see citing works
Liraz, O., Boehm-Cagan, A., & Michaelson, D. M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-16 · Cited by 118 · see citing works
ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease
Li, Y., Macyczko, J. R., Liu, C.-C., & Bu, G. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.03.011 · Cited by 61 · see citing works
Kloske, C. M., Belloy, M. E., Blue, E. E., Bowman, G. R., Carrillo, M. C., Chen, X., Chiba‐Falek, O., Davis, A. A., Paolo, G. D., Garretti, F., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13877 · Cited by 33 · see citing works
Flagged first, then by citations
- Authors
- Zheng, K., Tsitsos, F. N., Batts, A. J., Ji, R., Nuriel, T., Konofagou, E. E., & Leong, K. W.
- Affiliations
- Columbia University (US)
- Columbia University Irving Medical Center (US)
- Corresponding author
- Leong, Kam W.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2025-07
- Volume
- 21
- Issue
- 7
- Pages
- e70464-e70464
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC12263348
- OpenAlex
- W4412462235
- Cited by
- 8
- References
- 14
- Citations by year
- 2026: 6 · 2025: 2
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Focused Ultrasound Foundation
- Alexander S. Onassis Public Benefit Foundation (F ZT 072‐1/2023‐2024)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- focused ultrasound
- MeSH terms
- Gene Editing, Dependovirus, Animals, Blood-Brain Barrier, Brain, Genetic Vectors, Hippocampus, Humans, Mice, Inbred C57BL, Mice, Apolipoprotein E4, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
